Skip to search formSkip to main contentSkip to account menu

Pexidartinib

Known as: 3-Pyridinemethanamine, N-(5-((5-chloro-1H-pyrrolo(2,3-b)pyridin-3-yl)methyl)-2-pyridinyl)-6-(trifluoromethyl)- 
A capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antineoplastic… 
National Institutes of Health

Related topics

Related topics

3 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Narrower (1)

PLX3397

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Exploratory Process Development of Pexidartinib through the Tandem Tsuji–Trost Reaction and Heck Coupling
Abstract A novel synthetic route to CSF1R inhibitor pexidartinib was designed and demonstrated. Crucial to the successful… 
2019
2019
Phase 1 combination therapy with pexidartinib (PEX) and sirolimus (S) to target tumor-associated macrophages in pigmented villonodular synovitis, malignant peripheral nerve sheath tumors, and other…
11055 Background: No effective therapy exists for unresectable malignant peripheral nerve sheath tumors (MPNSTs). We previously… 
Review
2019
Review
2019
Pexidartinib for advanced tenosynovial giant cell tumor (TGCT): Long-term efficacy and safety from the phase 3 ENLIVEN and phase 1 PLX108-01 (TGCT cohort) studies.
11042 Background: TGCT is a rare, locally aggressive neoplasm of the joint/tendon sheath linked to colony-stimulating factor 1… 
2019
2019
[Pexidartinib inhibits the aggregation of monocytes into tumor microenvironment and reduces the number of M2 tumor-associated macrophages].
Objective To explore the effect of pexidartinib on the recruitment of monocytes into the tumor microenvironment and the… 
2019
2019
Tumor biological characteristics of Vestibular Schwannoma
The aim of this thesis is to shed light on the biological background of progression of sporadic vestibular schwannomas. The… 
2018
2018
A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of PLX9486 alone and in combination (combo) with the KIT inhibitors pexidartinib (pexi) or sunitinib (su) in patients (Pts) with advanced…
11509Background: Most metastatic GISTs have primary (10) mut in KIT exons (ex) 9 or 11, which confer sensitivity to imatinib and… 
2016
2016
ACTR-20. INITIAL RESULTS OF PLX108-08: AN OPEN LABEL PHASE 1B/2 STUDY OF ORALLY ADMINISTERED PEXIDARTINIB (PLX3397) IN COMBINATION WITH RADIATION THERAPY AND TEMOZOLOMIDE IN PATIENTS WITH NEWLY…
BACKGROUND: Pexidartinib (PEX) is a small molecule inhibitor of KIT and the CSF1 receptor expressed on microglia, blood vessels… 
2016
2016
Comparative biomarker profiles of pacritinib, momelotinib, pexidartinib, and ruxolitinib using BioMAP Diversity PLUS panel
2016
2016
A phase Ib study of pexidartinib (PLX3397) and weekly paclitaxel in patients with advanced solid tumors including an ovarian cancer subset
2016
2016
Phase 1/2a study of double immune suppression blockade by combining a CSF1R inhibitor (pexidartinib/PLX3397) with an anti–PD-1 antibody (pembrolizumab) to treat advanced melanoma and other solid…
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)